Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease

* Chronic hepatitis C virus (HCV) genotype 1a (GT1a) infection or genotype 4 (GT4) infection (HCV RNA level greater than 1,000 IU/mL at Screening). * Females must be post-menopausal, of non-child bearing potential or practicing specific forms of birth control. * Chronic kidney disease stage 4 or stage 5.

* Females who are pregnant or breastfeeding * Positive test result for Hepatitis B surface antigen (HBsAg) or anti-human immunodeficiency virus antibody (HIV Ab) * HCV genotype performed during screening unable to genotype or co-infection with any other HCV genotype, no mixed genotypes. * Abnormal laboratory tests * Current enrollment in another investigational study * Prior treatment with a direct acting antiviral agent (DAA) containing regimen with the exception of interferon or pegylated interferon with or without ribavirin * Current treatment with a direct acting antiviral agent (DAA) containing regimen * Any evidence of liver cirrhosis or liver cancer